Chagas disease is a neglected tropical disease caused by *Trypanosoma cruzi*, which was originally confined to Latin America. However, the prevalence of Chagas disease outside endemic areas has increased because of intense migrant flow and transmission by alternative routes ([@B23]). In Latin America, Chagas disease remains an important health problem, with 6-7 million people estimated to be chronically infected ([@B8]). The cardiac form of the disease affects 20-30% of chronically infected individuals and presents high morbidity and mortality due to heart failure (HF), sudden death, or stroke ([@B8]). Therefore, studies of the physiopathogenic aspects of patients who develop Chagas heart disease are extremely important. Changes in the immunologic system are considered one of the main mechanisms of disease progression. While patients with the indeterminate form present an immunologic balance between the host and parasite, patients who progress to the cardiac form present an inflammatory profile ([@B9]) with progressive heart tissue damage, cardiac remodelling, and myocardial fibrosis ([@B8]).

Transforming growth factor β1 (TGF-β1) is a profibrotic protein and multifunctional cytokine that has been implicated in Chagas disease physiopathology ([@B1]). Studies in animal models suggested that the TGF-β1-pathway is up-regulated during infection ([@B28], [@B4], [@B11]), promoting the intracellular parasite cycle ([@B37]) and inhibiting the immune response against the parasite ([@B32]), while the TGF-β1 pathway inhibition decreases parasitaemia and cardiac fibrosis and increases survival (de [@B7]). We and others previously showed that TGF-β1 is increased in patients with Chagas disease ([@B2], [@B22]) and has prognostic value ([@B30]). In contrast, others did not demonstrate increased myocardial TGF-β1 mRNA expression ([@B19]) or increased TGF-β1 serum levels in patients with Chagas heart disease ([@B36]).

Tumour necrosis factor (TNF) is a proinflammatory cytokine with increased expression in HF and may play a key role in the immunological imbalance governing Chagas disease progression to the cardiac form ([@B9]). Most studies have detected an increase in TNF measured in peripheral blood samples in patients with Chagas heart disease ([@B10], [@B16], [@B22], [@B34]) and some studies showed an increase in TNF in patients with the indeterminate form ([@B10], [@B34]). However, other studies showed no increase in TNF in the indeterminate form or even in patients with the cardiac form ([@B24], [@B13]).

Neurohormone brain natriuretic peptide (BNP) and the N-terminal segment of BNP (pro-BNP), which reflect diastolic pressure inside the left ventricle (LV), are elevated and predict the prognosis of HF ([@B12]). In Chagas disease, pro-BNP and BNP correlates with the LV ejection fraction and diastolic function and left atrial (LA) volume ([@B3]). Moreover, BNP and NTpro-BNP ([@B31]) are prognostic predictors of Chagas disease.

As both the TGF-β1 and TNF pathways are considered important in Chagas heart disease pathogenesis, we aimed to measure the serum levels of these proteins in non-infected individuals and patients with the indeterminate form or with different stages of the cardiac form. Additionally, we correlated both cytokines levels with LV systolic and diastolic functions and BNP serum values to evaluate their association with worsening cardiac performance.

SUBJECTS AND METHODS
====================

*Patients* - Patients with the indeterminate or cardiac form of Chagas disease followed at the outpatient service of the Evandro Chagas National Institute of Infectious Diseases were invited to participate in this cross-sectional study. Non-infected subjects were recruited from among those who were referred to our institution to investigate Chagas disease because of a positive epidemiological history but had negative Chagas disease serology. Non-infected subjects with LV systolic dysfunction were excluded. Chagas disease was diagnosed by a positive result in two different serological tests.

All subjects gave written informed consent before their participation. The study was approved by the local ethics committee under number 02826212.6.0000.5262 and conformed to the standards currently applied by the Brazilian National Committee for Research Ethics and Helsinki Declaration of 1975, as revised in 1983.

Patients with any of the following conditions were excluded from the study: previous treatment with benznidazole, co-infectious diseases, pregnancy, auto-immune diseases, cancer, associated cardiovascular diseases that difficult the classification of the cardiac form of Chagas disease, or associated digestive form of Chagas disease.

Patients were classified according to the current Brazilian Chagas disease consensus ([@B8]) as indeterminate (no evidence of cardiac involvement), stage A (asymptomatic with isolated changes in the electrocardiogram), stage B (asymptomatic with segmental or global LV systolic dysfunction), stage C (symptomatic HF), or stage D (end-stage HF). Race was self-reported.

*TGF-β1, TNF and BNP measurement* - TGF-β1, TNF and BNP measurements were performed by researchers blinded to the clinical classification of the patients. Measurement was performed using commercially available enzyme-linked immunosorbent assay kits (TGF-β1 and TNF: Quantikine ELISA Human ImmunoAssay, R&D Systems, Minneapolis, MN, USA; BNP: BNP-32 human EIA kit, Bachem, Bubendorf, Switzerland) according to the manufacturer's instructions. For total TGF-β1 dosage, all samples were assayed after acidic pH activation of latent TGF-β1.

*Echocardiography* - Echocardiograms were performed using a phased-array ultrasound system (Vivid 7, GE Medical Systems, Milwaukee, WI) equipped with an M4S phased-array transducer. Cardiac dimensions and Doppler measurements were obtained as previously described ([@B18]). M-mode echocardiography was used to measure LA, LV end-diastolic, and end-systolic diameters. The LV ejection fraction was determined by modified Simpson's rule with images obtained from apical 4- and 2-chamber views. Pulsed wave Doppler was obtained in the apical 4-chamber view. From transmitral recordings, the peak early (E) and late (A) diastolic filling velocities, E/A ratio, and E-wave deceleration time (DT) were obtained. Peak early (E') and late (A') diastolic myocardial velocities are the averages of the values obtained by spectral pulsed tissue Doppler of the mitral annulus at the septal and lateral positions.

*Statistical analysis* - Calculations were conducted using statistical software MedCalc 12.5.0.0. Continuous variables were expressed as the mean ± standard deviation (SD) and discrete variables as percentages. Except for BNP, all studied variables passed standard tests of normality (Kolmogorov-Smirnov test), allowing the use of parametric tests. Data between groups were compared by one-way analysis of variance followed by Student-Newman-Keuls post-hoc analysis. Correlation between echocardiographic parameters and biomarkers was evaluated using Pearson correlation coefficient. The strength of the studied correlations was classified as previously described ([@B39]). For statistical analysis, patients in stages C and D were grouped together as both groups were characterised by HF and stage D group had a small sample size. The null hypothesis was rejected at p *\<* 0.05.

RESULTS
=======

*Patient characteristics* - Of the total of 223 recruited subjects, 219 subjects consented to participate in the study. Blood samples were not collected from 14 subjects. Seven non-infected subjects were excluded because of dilated cardiomyopathy. Five patients were excluded because of previous treatment with benznidazole (1), hepatitis C virus coinfection (1), haemolysis of blood sample (1), and associated digestive form (2). The final studied population consisted of 193 subjects: 41 non-infected subjects, 53 patients with Chagas disease and no evidence of cardiac form, and 99 patients with the cardiac form of Chagas disease (24 stage A, 25 stage B, 44 stage C, and 6 stage D).

The mean age of the Chagas disease patients was 57 ± 12 years. Patients with the cardiac form were older than controls or patients with no evidence of the cardiac form. There was no difference in the frequency of racial categories across the studied groups. Co-morbidities were frequently present in patients with Chagas disease. Hypertension was present in 47% of patients, diabetes in 10% of patients, dyslipidaemia in 27% of patients, and coronary artery disease in 2% of patients; 4% of patients were current smokers. There was no significant difference in the frequency of co-morbidities among the studied groups. All patients with stages C or D of the cardiac form used renin-angiotensin system inhibitors, and most also used β-adrenergic blockers, furosemide, and aldosterone inhibitor. Most patients with stage B of the cardiac form also used renin-angiotensin system inhibitors ([Table I](#t1){ref-type="table"}).

TABLE IClinical characteristics Non-infected subjects (41)Chagas diseaseNo evidence of cardiac form (53)Stage A (24)Stage B (25)Stages C and D (50)Age (year)49 ± 1452 ± 1162 ± 11^\*†^60 ± 9^\*†^58 ± 13^\*†^Male (%)26.845.333.332.052Race (%)     White34.145.358.34850African-Brazilian9.711.312.52418Brown51.243.429.22832Not determined4.5\-\-\--Hypertension (%)48.847.245.960.042Diabetes (%)17.111.316.7010CAD (%)2.51.904.02Dyslipidemia (%)24.422.616.744.026Smoking (%)03.8012.02Medication (%)     ACE inhibitor-28175658ARB-8294042Spironolactone-002478Carvedilol-045696Amiodarone-082036Furosemide-042892Digoxin-00842Warfarin-082840[^2]

The place of origin of the patients is described by region and state in [Table II](#t2){ref-type="table"}. Most patients in all studied groups were born in the Northeast and Southeast regions. There were no significant differences in the region in which patients were born across the studied groups.

TABLE IIGeographic origin by region and state Non-infected subjects (41)Chagas diseaseNo evidence of cardiac form (53)Stage A (24)Stage B (25)Stages C and D (50)Northeast31 (75.6%)42 (79.2%)15 (62.5%)11 (44%)35 (70%)Bahia18 (44%)11 (21%)4 (17%)4 (16%)7 (14%)Paraíba4 (10%)10 (19%)4 (17%)2 (8%)8 (16%)Pernambuco1 (2%)3 (6%)2 (8%)3 (12%)7 (14%)Ceará4 (10%)11 (21%)1 (4%)1 (4%)6 (12%)Alagoas3 (7%)6 (11%)3 (12%)1 (4%)4 (8%)Sergipe-1 (2%)\--1 (2%)Piauí1 (2%)\-\--2 (4%)Rio Grande do Norte\--1 (4%)\--Southeast10 (24.4%)8 (15.1%)9 (37.5%)12 (48%)12 (24%)Minas Gerais6 (14%)4 (7%)7 (29%)11 (44%)10 (20%)Rio de Janeiro4 (10%)3 (6%)2 (8%)1 (4%)2 (4%)Espírito Santo-1 (2%)\-\--South03 (5.7%)000Rio Grande do Sul-2 (4%)\-\--Paraná-1 (2%)\-\--North00001 (2%)Pará\-\-\--1(2%)Midwest0002 (8%)2 (4%)Goiás\-\--2 (8%)2 (4%)

Electrocardiogram findings were more frequent in patients with the cardiac form of Chagas disease, as expected because of Chagas disease classification criteria. Some isolated electrocardiographic changes were not sufficient to indicate that the patient had the cardiac form of disease ([@B8]). Thus, among patients in the group with no evidence of the cardiac form, two presented left anterior hemiblock and one low QRS voltage. Right bundle branch block, left anterior hemiblock, and primary ST-T wave changes were the most common electrocardiographic changes among patients with the Chagas disease cardiac form. Patients with pacemaker implants were present in all stages of the cardiac form, but most cases were detected in patients with stage C or D of the cardiac form ([Table III](#t3){ref-type="table"}). Left bundle branch block was also observed in three patients with stage A and two patients with stage B of the cardiac form.

TABLE IIIElectrocardiographic and echocardiographic characteristics Non-infected subjects (41)Chagas DiseaseNo evidence of cardiac form (53)Stage A (24)Stage B (25)Stages C and D (50)ECG (%)     RBBB12.2062.5^\*†^32.0^†‡^46.0^\*†^Low QRS voltage01.94.212.020.0^\*†‡^LAHB4.93.845.8^\*†^36.0^\*†^46.0^\*†^Electrically inactive area2.404.216.0^†^14.0^†^Primary ST-T wave changes9.80\*29.2^†^40.0^\*†^48.0^\*†^Pacemaker008.316.0^\*†^24.0^\*†^EchocardiogramLA (mm)36 ± 436 ± 439 ± 6^\*†^41 ± 5^\*†^45 ± 5^\*†‡\#^LVd (mm)49 ± 550 ± 451 ± 356 ± 6^\*†‡^68 ± 7^\*†‡\#^LVs (mm)29 ± 430 ± 431 ± 439 ± 8^\*†‡^56 ± 8^\*†‡\#^EF (%)68 ± 771 ± 769 ± 957 ± 14^\*†‡^35 ± 11^\*†‡\#^E/A (ratio)1.4 ± 0.61.2 ± 0.51.0 ± 0.51.0 ± 0.32.1 ± 1.3^\*†‡\#^DT (ms)173 ± 42179 ± 59190 ± 51185 ± 78159 ± 81E' (cm/s)10.7 ± 4.19.4 ± 2.8^\*^7.7 ± 2.1^\*†^6.8 ± 2.7^\*†^5.3 ± 1.9^\*†‡\#^E/E'8.8 ± 3.48.2 ± 2.69.3 ± 3.613.0 ± 6.6^\*†‡^18.6 ± 7.9^\*†‡\#^[^3]

*Echocardiogram findings* - LA and LV diameters were larger and LV ejection fraction was lower in stage B and stages C and D patients than in other groups. LA diameter was also larger in stage A patients than in patients with the indeterminate form or in non-infected subjects. Parameters of LV diastolic function showed progressive worsening of the LV diastolic function across the stages of the cardiac form of Chagas disease. The E' velocity was lower in stage A patients than in non-infected subjects and patients with no evidence of the cardiac form, and progressively decreased in patients with stage C and D of the cardiac form. In contrast, the E/E' ratio was higher among patients with stage B than in non-infected subjects, patients with no evidence of the cardiac form, and patients in stage A. The E/E' ratio further increased in patients in stages C and D of the cardiac form ([Table III](#t3){ref-type="table"}).

*TGF-β1, TNF and BNP serum values* - TGF-β1 serum values were lower in stages B, C and D of the cardiac form than in non-infected subjects and patients with no evidence of the cardiac form. TNF serum values were higher in patients in stages C and D of the cardiac form than in non-infected subjects and patients with no evidence of the cardiac form.

BNP serum levels were higher in patients who presented HF (stages C and D of the cardiac form) than in all other groups ([Table IV](#t4){ref-type="table"}).

TABLE IVSerum values of transforming growth factor β1(TGF-β1), tumor necrosis factor (TNF) and brain natriuretic peptide (BNP) Non-infected subjects (41)Chagas diseaseNo evidence of cardiac form (53)Stage A (24)Stage B (25)Stages C and D (50)TGF-β1 (ng/mL)48 ± 1048 ± 1145 ± 1042 ± 10^\*†^42 ± 12^\*†^TNF (pg/mL)3.2 ± 2.13.5 ± 4.33.9 ± 4.83.4 ± 2.96.4 ± 7.4^\*†^BNP (pg/mL)157 ± 123178 ± 171240 ± 165387 ± 4921224 ± 1615^\*†‡\#^[^4]

*TGF-β1 and TNF serum levels and LV function* - The correlation between TGF-β1 and TNF serum levels and parameters of LV systolic and diastolic function and BNP serum levels were evaluated only in the population with Chagas disease. TGF-β1 presented a fair negative relationship with E/E' ratio (r = -0.25; p = 0.002) and slightly positive correlation with LV ejection fraction (r = 0.18; p = 0.02) and fair positive correlation with E' velocity (r = 0.26; p = 0.002; [Fig. 1](#f01){ref-type="fig"}). TGF-β1 did not show a significant correlation with LA or LV diameters, E/A ratio, DT and BNP serum levels.

Fig. 1: correlation between transforming growth factor β1 (TGF-β1) serum levels and echocardiographic parameters. TGF-β1 presented a slightly positive correlation with left ventricular ejection fraction (LV EF) (A) and fair negative relationship with peak early diastolic filling and diastolic myocardial velocities (E/E') ratio (B).

TNF presented a slightly positive relationship with LA (r = 0.16; p = 0.04) and end-systolic LV diameters (r = 0.16; p = 0.04) and slightly negative correlation with LV ejection fraction (r = -0.20; p = 0.01; [Fig. 2](#f02){ref-type="fig"}). TNF was not significantly correlated with any LV diastolic function parameters or BNP serum levels.

Fig. 2: correlation between tumour necrosis factor (TNF) serum levels and echocardiographic parameters. TNF presented a slightly negative relationship with left ventricular ejection fraction (LV EF) (A) and slightly positive correlation with end-systolic LV diameter (LVDs) (B).

We also tested the correlation between TGF-β1 and TNF serum levels and echocardiographic parameters and BNP after excluding all patients with hypertension, diabetes, and any history of coronary artery disease. This comprised a population of 72 patients. In this subpopulation, TGF-β1 still presented a fair positive correlation with E' velocity (r = 0.36; p = 0.002) and E/A ratio (r = 0.26; p = 0.03), and a nearly significant fair negative correlation with BNP (r = -0.21; p = 0.07). TNF did not present significant correlations with echocardiographic parameters or BNP in this subpopulation.

In contrast, BNP serum levels showed better correlations with echocardiographic parameters of LV diastolic and systolic function than TGF-β1 and TNF. BNP serum levels showed a skewed distribution, and log-transformation was applied before correlation analysis. BNP presented a substantially positive correlation with end-systolic LV diameter (r = 0.62, p \< 0.0001) and substantially negative correlation with LV ejection fraction (r = -0.63, p \< 0.0001). BNP presented a moderately positive correlation with end-diastolic LV diameter (r = 0.55, p \< 0.0001), LA diameter (r = 0.46, p \< 0.0001), and E/E' ratio (r = 0.59, p \< 0.0001) and moderately negative correlation with E' velocity (r = -0.47, p \< 0.0001). BNP also presented a fair positive correlation with E/A ratio (r = 0.35, p \< 0.0001) and negative correlation with DT (r = -0.21, p = 0.01). We also analysed the correlation between BNP and echocardiographic parameters in the subpopulation after excluding all patients with hypertension, diabetes, and any history of coronary artery disease. BNP still presented a substantial positive correlation with end-systolic LV diameter (r = 0.66, p \< 0.0001) and E/E' ratio (r = 0.65, p \< 0.0001) and negative correlation with LV ejection fraction (r = -0.70, p \< 0.0001). BNP still presented a moderately positive correlation with end-diastolic LV diameter (r = 0.54, p \< 0.0001), LA diameter (r = 0.49, p \< 0.0001) and moderately negative correlation with E' velocity (r = -0.48, p \< 0.0001). BNP also still presented a fair positive correlation with E/A ratio (r = 0.38, p = 0.001) and negative correlation with DT (r = -0.38, p = 0.001).

DISCUSSION
==========

This is the first study to explore the correlation between TGF-β1 and TNF serum levels and both LV systolic and diastolic functions in patients with Chagas disease. Chagas cardiomyopathy is a complex disease that affects approximately 30% of individuals infected with *T. cruzi*. However, previous studies have not reliably predicted which patients will evolve to Chagas cardiomyopathy. Persistence of the parasite within the myocardium and the immune response elicited by such persistence have been proposed to play a key role in Chagas disease progression ([@B9]). In contrast, a recent randomised clinical trial known as BENEFIT evaluated the efficacy of benznidazole in modifying the clinical outcomes of patients with chronic Chagas heart disease. A reduction of circulating parasite abundance but a lack of clinical effect on cardiac outcome was observed in a 5-year follow-up study. However, the previous study did not evaluate whether benznidazole treatment modifies progression from the indeterminate to the cardiac form ([@B17]). The abundance of inflammatory cytokines may favour Chagas disease progression, while abundance of anti-inflammatory cytokines may favour persistence of the Chagas disease indeterminate form. In this context, several studies demonstrated increased serum levels of inflammatory cytokines among patients with the Chagas disease cardiac form, while other studies revealed an increase in anti-inflammatory cytokines in patients with the indeterminate form ([@B9], [@B5]). Some cytokines may have prognostic value and be correlated with LV function. However, few studies explored the correlation between cytokines serum levels with LV function.

The Chagas disease population followed at our outpatient facility was older compared to those studied previously by our group ([@B29]). A consequence of this process is the high prevalence of co-morbidities in our studied sample. We did not exclude patients with co-morbidities from our study because we aimed to evaluate cytokine expression and its correlation with LV function in the scenario commonly found in everyday clinical practice. Our echocardiographic data confirmed the worsening of LV systolic and diastolic function according to Chagas disease classification, as we demonstrated previously ([@B18]). The low mean LV ejection fraction, large LV diameters, and high BNP serum levels of patients with stages C and D of the cardiac form reveal the severity of heart disease. BNP serum levels presented significant correlations with all tested echocardiogram parameters.

We found that TNF serum levels were increased only in patients with severe stages of the cardiac form associated with HF. Previous studies found elevated TNF serum levels only in patients with Chagas disease HF ([@B22]), while others detected elevated TNF serum levels elevated in both indeterminate and Chagas disease HF patients ([@B10]). Other studies ([@B16], [@B34]) of increased TNF serum levels in patients with the Chagas disease cardiac form did not divide the patients with HF into a separate group for analysis. The number of TNF-producing inflammatory cells within the myocardium is higher in patients with Chagas disease and HF than in patients with the cardiac form and no HF ([@B27]). TNF showed a positive correlation with LV end-diastolic diameter and negative correlation with LV ejection fraction in patients with Chagas disease ([@B16]), while others studies found this same correlation only in patients with the cardiac form of Chagas disease ([@B34]). TNF was also found to be positively correlated with BNP serum levels ([@B36], [@B16]). However, the previous studies did not evaluate the correlation between TNF and LV diastolic function. LV diastolic function is frequently present in Chagas disease and its prevalence increases from the mild to more severe stages of the Chagas disease cardiac form ([@B18]). Moreover, LV diastolic function indices have prognostic value in Chagas disease ([@B18]). Therefore, TNF serum levels may correlate with LV diastolic function. In our study, TNF presented a weakly positive relationship with the LA and end-systolic LV diameters and weakly negative correlation with the LV ejection fraction. These results confirm previous findings showing that TNF is correlated with LV systolic function and add the information that TNF correlates with LA diameter, which is an important index of cardiac function. However, in our study, TNF was not correlated with LV diastolic function or BNP and the correlation with LV diameter or ejection fraction was weaker than that described previously ([@B16], [@B34]). This may be related to the fact that our patients were older and had a high prevalence of co-morbidities. However, the exclusion of patients with co-morbidities did not increase the strength of the correlation between TGF-β1 or TNF serum levels and BNP or echocardiographic parameters. Another possible reason for the weak correlations between TNF serum levels and echocardiographic parameters is the known effect of cardiovascular drugs used to treat HF on TNF serum levels. Carvedilol ([@B35]), spironolactone ([@B20]), and angiotensin-converting enzyme inhibitors ([@B15]) decreased TNF serum levels in patients with HF.

Our study revealed a decrease in TGF-β1 serum levels in patients with stages B, C, and D of the cardiac form. We also demonstrated that TGF-β1 had a weak negative relationship with the E/E' ratio and weak positive correlation with the LV ejection fraction and E' velocity, indicating that TGF-β1 serum levels decrease with worsening LV systolic and diastolic LV functions. Although we previously found that TGF-β1 was increased in patients with Chagas disease ([@B2]), we did not confirm this finding in our new patient sample. Other studies also did not detect increased TGF-β1 serum levels in patients with Chagas disease and HF compared to in non-infected subjects ([@B36]). Another study found an increase in TGF-β1 serum levels only in patients with the stage A of the cardiac form ([@B6]), while TGF-β1 serum levels did not differ between controls and patients with the Chagas disease indeterminate form or more advanced stages of Chagas disease cardiac form. Histopathological studies found no increase in myocardial TGF-β1 mRNA expression in patients with Chagas heart disease compared to in non-infected subjects ([@B19]). Others also found a low prevalence of TGF-β1-positive cells within the myocardium of patients with Chagas disease and HF ([@B26]). The number of TGF-β-producing inflammatory cells within the myocardium was also found to be similar between patients with Chagas disease cardiac form with or without HF ([@B27]). One possible explanation for these discrepant results is the different age range of the patients and time living away from endemic areas between studies. The present study included a larger sample of patients than previous studies ([@B2], [@B22]) and patients included in the present study were older and/or lived for a longer time away from endemic areas than those in previous studies ([@B2], [@B22]). Patients who still live in endemic areas or had a lower length of time since their last exposure to new *T. cruzi* infection may show more enhanced activation of the TGF-β1 signalling pathway and different TGF-β1 serum levels than older patients who have lived away from endemic areas for several decades. Moreover, TGF-β1 production depends on the immune response type of each patient, which may be mediated by host genetic factors and medication administered for HF, among other reasons. Regarding medication, patients in the present study were treated with drugs that improved the survival of HF ([@B33], [@B21], [@B25]), but decreased TGF-β transcription, such as angiotensin-converting enzyme inhibitor ([@B14]), spirolactone ([@B40]), and carvedilol ([@B38]). A previous study from our group was performed on blood samples collected between 1998 and 1999 ([@B2]). At that time, patients were not regularly treated with carvedilol or spironolactone, as trials that demonstrated the beneficial effects of these drugs on HF were published a short time before the study ([@B21], [@B25]). In the present study, the percentage of patients with HF using carvedilol, angiotensin-converting enzyme inhibitor, and spirolactone was high, similarly to in another study that detected no difference in TGF-β1 serum levels between controls and patients with HF due to Chagas disease ([@B36]).

Therefore, although experimental studies showed that TGF-β1 may have a key role in Chagas disease infection and progression, studies of TGF-β1 serum levels in clinical practice have shown inconsistent results and may not be useful as a surrogate for increased risk of progression or disease severity.

In summary, TNF and TGF-β1 serum levels presented a weak correlation with LV systolic and diastolic functions in patients with Chagas disease. While TNF were increased in patients with Chagas disease HF, TGF-β1 serum levels were decreased in patients with stages B, C, and D of the cardiac form. BNP serum levels were increased only in patients with Chagas disease HF.
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